Human Longevity Inc has expanded its $1 million Cancer Prevention Pledge to include late-stage ovarian cancer, aiming to help at-risk women detect disease earlier through whole-genome sequencing and multi-cancer early detection screening, according to the company.
The company said the pledge will fund preventive screening services for women identified as genetically predisposed to ovarian cancer. This expansion builds on Human Longevity’s original initiative, launched in April, which focused on reducing late-stage cancer diagnoses across several cancer types.
Human Longevity claims its integrated approach combines advanced genomic testing with imaging and blood-based multi-cancer detection, aiming to catch cancers before they progress to later stages where survival rates decline sharply.
The expanded pledge targets ovarian cancer due to its typically asymptomatic progression and high mortality rate when diagnosed late. The company said that identifying high-risk women earlier could significantly improve outcomes.
The Cancer Prevention Pledge is part of Human Longevity’s broader strategy to advance personalized and preventive medicine through genomics-driven risk assessment. By covering the cost of advanced screenings, the initiative aims to remove financial barriers that often limit access to early detection technologies.
According to the company, this program also underscores its commitment to translating genetic insights into actionable prevention strategies that could reduce late-stage cancer diagnoses and improve survival rates among high-risk populations.
